Welcome to our dedicated page for AKTIS ONCOLOGY news (Ticker: AKTS), a resource for investors and traders seeking the latest updates and insights on AKTIS ONCOLOGY stock.
Aktis Oncology, Inc. (Nasdaq: AKTS) is a clinical-stage oncology company focused on targeted radiopharmaceuticals for solid tumors, and its news flow reflects this specialization. Company announcements emphasize progress in its miniprotein radioconjugate platform, which is designed to deliver radioisotopes selectively to tumors while limiting exposure to normal tissues.
News related to Aktis Oncology includes capital markets milestones, such as the closing of its upsized initial public offering and the start of trading on the Nasdaq Global Select Market under the AKTS ticker. These updates provide context on how the company is financing its research and development activities in targeted alpha radiopharmaceuticals.
Investors and observers can also expect coverage of pipeline developments. Aktis Oncology has highlighted programs such as AKY-1189 and AKY-2519, as well as its most advanced program targeting Nectin-4 with a miniprotein radioconjugate that it describes as having multi-indication potential across multiple tumor types. News may discuss clinical progress, platform refinements, and efforts to expand the reach of its radiopharmaceutical candidates to larger patient populations.
Another recurring theme in Aktis Oncology news is its strategic collaboration with Eli Lilly and Company, which is intended to apply the company’s miniprotein platform to novel radioconjugates outside its proprietary pipeline. Updates may reference how this collaboration fits into the company’s broader strategy.
For readers following AKTS, the news page offers a way to track developments in its clinical programs, financing events, and partnership activities over time. Regularly reviewing this coverage can help provide a clearer picture of how the company’s radiopharmaceutical platform and solid tumor pipeline are evolving.
Akoustis Technologies (NASDAQ: AKTS) introduced a new chip scale package (CSP) to enhance its XBAW filter product line for 5G mobile and WiFi 6E devices. The CSP is set to enter qualification in Q2 of 2021, with production anticipated in the latter half of the year. This development supports rapid prototyping and flexible capacity through both in-house and outsourced manufacturing. The company aims to boost its annual production capacity to 500 million filters by year-end, responding to a growing sales funnel in the 5G and WiFi markets.
Akoustis Technologies (AKTS) reported record revenue of $2.5 million for Q3 FY2021, a 92% increase sequentially, surpassing analyst expectations by 11%. The company saw a substantial rise in XBAW filter shipments, over 100% sequentially, reflecting growing customer demand in 5G and WiFi markets. With $90.4 million in cash, Akoustis plans to double production capacity by year-end 2021. Recent accomplishments include the shipment of new WiFi 6E filters and ongoing production for tier-1 clients. The company remains optimistic about significant revenue growth driven by market opportunities in 5G and WiFi technologies.
Akoustis Technologies (NASDAQ: AKTS) has expanded its intellectual property portfolio with the issuance of nine new patents, bringing the total to 47 issued patents and 78 pending as of April 23, 2021. These patents focus on BAW resonators, piezoelectric materials, and various RF filter technologies for 5G and WiFi 6 applications. The company is ramping up production capacity at its New York facility and aims to deliver innovative solutions to meet increasing market demands in mobile and wireless sectors.
On April 26, 2021, Akoustis Technologies (NASDAQ: AKTS) announced an investor update call scheduled for May 3, 2021, at 8:00 a.m. ET. The call will include a business update and a Q&A session. The company is actively producing WiFi 6 tandem filter solutions and shipping multiple 5G small cell XBAW® filters. Akoustis has recently expanded its product catalog with 15 new filters, including those for WiFi and 5G applications. The firm leverages advanced manufacturing techniques to support the growing RF filter market.
Akoustis Technologies (NASDAQ: AKTS) has announced new WiFi 6E XBAW filter modules enhancing the 5 GHz WiFi spectrum. The 5.6 GHz and 6.6 GHz modules enable the utilization of additional 80 MHz and 160 MHz channels across the UNII 1-4 and UNII 5-8 bands. A tier-1 OEM has placed the first order for these filters, aimed at developing MU-MIMO products. Commercial production is anticipated in late 2021 to early 2022. The company's strategy includes expanding its New York manufacturing facility to support growing demand.
On April 5, 2021, Akoustis Technologies (NASDAQ: AKTS) announced that its XBAW WiFi 6E coexistence filter solutions received approval for use in multiple chipsets from a tier-1 SoC manufacturer. The filters cover crucial frequency bands for WiFi 6E devices. The company is experiencing rapid acceptance of its products, which is expected to broaden its sales channels. Additionally, Akoustis plans to expand production capacity in New York, addressing the growing demand for high-performance RF filters as global governments allocate new wireless spectrums.
Akoustis Technologies (NASDAQ: AKTS) announced a significant milestone by securing a WiFi 6E reference design with a Tier 1 SoC vendor. This design utilizes the 5.5 GHz and 6.5 GHz XBAW filter modules, enhancing sales opportunities for Akoustis's filters in next-gen routers. The reference design is expected to be available in the second half of calendar 2021. With the FCC's recent approval of additional unlicensed spectrum, demand for high-performance filters is expected to rise. Akoustis is also ramping up production capacity to meet the increasing demand for its RF filter solutions.
Akoustis Technologies (NASDAQ: AKTS) announced its participation in the 33rd Annual Roth Conference from March 15-17, 2021. The company’s management will engage in a fireside chat at 11:00 am ET on March 15, which will be webcast live. Akoustis is focused on high-performance XBAW® RF filters for 5G, WiFi, and radar applications, entering production across multiple markets in 2020. The company plans to expand its New York fabrication facility due to a growing backlog and is launching several new filter products to meet increasing demand.
Akoustis Technologies (NASDAQ: AKTS) announced that holders of its 6.5% Convertible Senior Notes due 2023 converted their notes into equity, resulting in the issuance of 4,983,633 shares of common stock. This discharge of indentures eliminates all associated liens, enhancing the company’s financial standing. Akoustis is ramping up production of its XBAW® RF filters for various applications, including 5G and Wi-Fi, and plans to expand its manufacturing capacity in New York to meet growing demand.
Akoustis Technologies, Inc. (NASDAQ: AKTS) announced its participation in the Loop Capital 2021 Investor Conference on March 11-12, 2021. The event will be conducted virtually due to Covid-19. Interested investors can schedule meetings via their Loop Capital representative or by reaching out to Akoustis’ investor relations. The company has seen increasing interest in its XBAW® RF filters, which support 5G applications, high-band WiFi, and radar systems. Akoustis is also expanding production capacity in New York to meet growing demand for its new filters and solutions.